EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort  by Varella-Garcia, Marileila et al.
ORIGINAL ARTICLE
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell
Lung Cancer After Surgery
Impact on Outcome to Treatment with Gefitinib and Association
with EGFR and KRAS Mutations in a Japanese Cohort
Marileila Varella-Garcia, PhD,* Tetsuya Mitsudomi, MD,† Yashushi Yatabe, MD,‡
Takayuki Kosaka, MD,† Eiji Nakajima, MD,* Ana Carolina Xavier, MD,* Margaret Skokan, BS,*
Chan Zeng, PhD,* Wilbur A. Franklin, MD,* Paul A. Bunn, Jr., MD,*
and Fred R. Hirsch, MD, PhD*
Background: Sensitivity to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) and frequency of acti-
vation mutations in EGFR is lower in Caucasian than Asian non
small-cell lung cancer (NSCLC) patients. Increased EGFR gene
copy numbers evaluated by fluorescence in situ hybridization
(FISH) has been reported as predictor of clinical benefit from
EGFR-TKIs in Caucasian NSCLC patients. This study was car-
ried out to verify whether EGFR FISH had similar performance
in Japanese patients.
Methods: A cohort of 44 Japanese patients with recurrent NSCLC
after surgery was treated with gefitinib 250 mg daily. The cohort
included 48% females and 52% never-smokers; 73% had prior
chemotherapy and 57% had stage III-IV at the time of surgery.
Adenocarcinoma was the most common histology (86%). FISH was
performed using the EGFR/Chromosome Enumeration Probe 7 and
PathVysion DNA probes (Abbott Molecular). Specimens were clas-
sified as FISH positive when showing gene amplification or high
polysomy (4 copies of the gene in 40% of tumor cells). Tumor
response to gefitinib was assessed by RECIST for 33 patients with
measurable diseases.
Results: Twenty-nine tumors (66%) were EGFR FISH and 23
(53%) were HER2 FISH. Overall response rate was 52%, repre-
senting 65% of EGFR FISH patients and 29% of EGFR FISH
patients (p  0.0777). Survival was not impacted by the EGFR
FISH (p  0.9395) or the HER2 FISH (p  0.0671) status. EGFR
FISH was significantly associated with HER2 FISH (p 0.015)
and presence of EGFR mutation (p  0.0060). EGFR mutation
significantly correlated with response (p  0.0001) and survival
after gefitinib (p  0.0204). EGFR and HER2 FISH status were not
associated with KRAS mutation.
Conclusion: Frequency of EGFR FISH status was higher and its
predictive power for TKI sensitivity was lower in this Japanese
cohort than in Western NSCLC cohorts. These findings support
differences in the mechanisms of EGFR pathway activation in
NSCLC between Asian and Caucasian populations. Confirmation of
these results in larger cohorts is warranted.
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Tyrosine inhibitors.
(J Thorac Oncol. 2009;4: 318–325)
Tumor dependence on specific molecular pathways mayidentify the best target for therapy exploration. Activation
of the epidermal growth factor receptor (EGFR)-related sig-
naling pathways drives numerous cancer-promoting pro-
cesses, such as cell proliferation, apoptosis inhibition, angio-
genesis, cell adhesion, and motility and invasion, and also
controls development of drug resistance.1 Therefore, anti-
EGFR approaches (antibodies directed against the extracel-
lular domain and small inhibitors of the tyrosine kinase
activity) have been one of the most successful examples of
molecular target therapy in human solid neoplasias, mainly in
*University of Colorado Cancer Center, Aurora, Colorado; †Departments of
Thoracic Surgery, Pathology, and Molecular Diagnostics; and ‡Aichi
Cancer Center Hospital, Nagoya, Japan.
Disclosure: Dr. Hirsch has served on advisory boards for AstraZeneca,
Pfizer, Merck Serono, BMS/Imclone, Syndax, Boehringer Ingelheim,
Roche, and Lilly. He has received research grants from Astra Zeneca,
OSI, Genentech, Syndax, and Merck. He is also the co-inventor of a
University of Colorado owned patent: EGFR FISH As a Predictive
Marker for EGFR Inhibitors (patent licensed to Abbot Diagnostics). Dr.
Varella-Garcia received honorarium from Abbott Molecular to speak at
the Association for Molecular Pathology annual meeting in 2008 about
the EGFR FISH assay. She is also a co-inventor of a patent for use of the
EGFR FISH assay to select NSCLC patients for therapy. Dr. Mitsudomi
has received honorarium for speaking to a professional group from
AstraZeneca and Chugai Pharmaceutical. He also provided testimony in
court for gefitinib. Dr. Bunn was paid an honorarium and travel expenses
by GlaxoSmithKline to attend an advisory board on the MAGG A3
vaccine. A clinical trial using the vaccine is being conducted at the Univer-
sity of Colorado Cancer Center. Dr. Bunn is not the PI and received no
funding for this trial.
Address for correspondence: Dr. Fred R. Hirsch, University of Colorado
Cancer Center, Department of Medicine and Pathology, PO Box 6511,
Mails stop 8117, Aurora, CO 80045. E-mail: fred.hirsch@uccdenver.edu
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0403-0318
Journal of Thoracic Oncology • Volume 4, Number 3, March 2009318
non small-cell lung cancer (NSCLC), head and neck, pancre-
atic and colorectal carcinomas.2
Targeted therapies are expected to be effective when
the targeted molecule is a major player in the tumor cellular
processes, which usually does not occur in all patients with
any specific solid tumor. Strategies for patient selection for
targeted therapy are almost universally considered to be
necessary but are not fully implemented, even for anti-EGFR
therapies. In NSCLC, causally associated with EGFR activa-
tion are mutations in the adenosine triphosphate-binding site
of the tyrosine kinase domain that sustain abnormal response
to the ligand,3,4 activate multiple signaling transduction path-
ways5,6 and selectively activate AKT and signal transducers
and activators of transcription signaling.6,7 Increased gene
copy numbers is also a well known mechanism for activation
of EGFR-related pathways in gliomas,8 breast,9 colon,10 head
and neck cancers,11and NSCLC.12
In NSCLC, at least three molecular markers have been
consistently associated with sensitivity or resistance to
EGFR-TKIs (tyrosine kinase inhibitors): mutations and am-
plification/overrepresentation of the EGFR gene3–5,12–14 and
mutation in the KRAS genes.15–18 The impact on survival has
been extensively investigated for activating EGFR muta-
tions,19 and less for the EGFR gene copy numbers12,14,20,21 or
for the KRAS mutations16,22 and results among studies have
not been totally concordant. Distinct technologies have been
used to identify mutations and genomic gain and part of the
discrepancies among results from different studies may due to
technical factors. However, other factors such as smoking
status, gender, and ethnicity have been demonstrated to im-
pact sensitivity to EGFR-TKIs. Patients of Eastern Asian
origin have significantly better clinical outcome to EGFR-
TKIs than western populations23,24 but reasons for these
differences are not completely understood. The most impor-
tant factor so far accounting for this finding is that the Asian
NSCLC patients including Japan, have high incidence of
activating EGFR mutations.4,25
This study aimed to verify the role of EGFR genomic
gain as a marker for sensitivity to gefinitib in a Japanese
cohort using fluorescence in situ hybridization (FISH), a
technology proved to be successful for prediction of outcome
to EGFR TKIs in some Caucasian NSCLC populations. In
addition, the study aimed to compare EGFR genomic gain
with two other gefitinib-related markers, activating mutations
in EGFR and resistant mutations in KRAS, which were
previously investigated in this cohort.13
PATIENTS AND METHODS
Description of Patient Population and Definition
of Effectiveness of Gefitinib Treatment
From a population of NSCLC patients who underwent
surgery between 1999 and 2003 in the Aichi Cancer Center
Hospital in Nagoya, Japan, 75 had recurrent disease and were
treated with 250 mg/daily of gefitinib for recurrent disease.
From those, response to treatment could not be evaluated in
6 cases, tumor material was not available in 24 cases, and FISH
analyses failed in 4 cases. Thus, the current study reports on 44
patients, all of whom provided consent for the study.
Tumor materials obtained at initial tumor resection for
these 44 NSCLC cases had been previously investigated for
EGFR and KRAS mutations.13,16 Tumor response to gefitinib
treatment was evaluated for 33 patients eliminating 11 pa-
tients who did not have measurable diseases. Tumor response
was judged according to the RECIST, without requirement of
confirmation of tumor response no less than 4 weeks apart.
The length of gefitinib therapy was used as a surrogate for
disease free survival and overall survival was calculated form
the start of gefitinib administration to death from any cause or
the most recent date on which the patient was known to be alive.
EGFR and HER2 Fluorescence In Situ
Hybridization Assays
Formalin-fixed, paraffin-embedded tumor blocks
were sectioned at 4 m and submitted to dual-color FISH
assays using the Locus Specific Indicator EGFR Spectrum-
Orange/CEP 7 SpectrumGreen and the PathVysion DNA
Probe Kit (HER2 SpectrumOrange/CEP 17 SpectrumGreen
Vysis/Abbott Molecular) following protocol previously de-
scribed.12 Briefly, slides were deparaffinized in CitriSolv
(Fisher Scientific) and washed in 100% ethanol for 5 minutes.
The slides were then sequentially incubated in 2 SSC
(saline sodium citrate) at 75°C for 13 to 18 minutes, digested
in 0.25 mg/ml Proteinase K/2 SSC at 45°C for 14 to 18
minutes, washed in 2 SSC for 5 minutes and dehydrated in
ethanol series. Probes were applied according to the manu-
facturer instructions to the selected hybridization areas,
which were covered and sealed. DNA denaturation was
performed in dry oven for 15 minutes at 80°C and hybrid-
ization was allowed to occur for 20 hours at 37°C in a
humidified chamber. Posthybridization washes were per-
formed consecutively in 2 SSC/0.3% NP-40 at 72°C and
2 SSC for 2 minutes each. Following dehydration in etha-
nol, chromatin was counterstained with 4’  6-diamidino-2-
phenylindole (DAPI) (0.3 g/ml in antifade Vectashield
mounting medium, Vector Laboratories). Analysis was per-
formed on epifluorescence microscopes using single interfer-
ence filters sets for green, red (Texas red) and blue (DAPI) as
well as dual (red/green) and triple (blue, red, green) band pass
filters. For documentation, images were acquired using
charged-coupled device camera with Z-stacking and merged
using dedicated software (CytoVision, Applied Imaging).
At least 50 tumor nuclei were analyzed in tumor areas
selected using the correspondent HE stained slide as a guide.
Scoring system followed previous publications.12 According
to the frequency of tumor cells with specific number of copies
of the gene and the CEP targets, the tumors were initially
classified into six FISH categories (disomy, low and high
trisomy, low and polysomy, and gene amplification) and
finally grouped into two strata: (a) FISH negative including
disomy to low polysomy tumors, which basically have 4
copies of the gene in 40% of cells; and (b) FISH positive
including tumors with high polysomy (4 copies in40% of
cells) and gene amplification (defined by a ratio gene/chro-
mosome per cell 2, presence of small or nonenumerable
clusters of the gene signal or15 copies of the gene signal in
10% of the analyzed cells).
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Statistical Analysis
For comparisons of proportions, the Pearson’s 2 test or
the Fisher’s exact test was used. Nonparametric Wilcoxon
rank sum test or Kruskal-Wallis test was used to compare the
difference in continuous variables. The Kaplan-Meier method
was used to estimate the probability of survival as a function
of time, and survival differences between groups were ana-
lyzed by the log-rank test. The two-sided significance level
was set at p  0.05. All analyses were performed using SAS
version 9.1 (SAS Institute Inc, Cary, NC) software.
RESULTS
Clinical and demographical characteristics are summa-
rized in Table 1. The patients were evenly split between
males and females, never or ever smokers and with early or
advanced stage disease. Adenocarcinoma histology and
poorly or moderately differentiated histologic grade were
prevalent. Most patients had not received prior chemother-
apy. Median disease free interval after surgery was 375 days,
median survival after gefitinib treatment was 562 days, and
66% of patients were alive at the time of last follow up.
EGFR FISH and mutation status in relation to demo-
graphics are summarized in Table 2. While EGFR mutation
was associated with female gender, never-smoking status,
and adenocarcinoma histology, none of these was related
with EGFR-FISH status.
Distribution of patients through the FISH categories is
illustrated in Figure 1A for the EGFR gene and Figure 1B for
the HER2 gene. The majority of tumors (29 cases [66%])
were EGFR FISH positive, predominantly due to a large
representation of tumors with high polysomy (23 cases, 52%,
Figure 2A) rather than gene amplification (6 cases, 14%,
Figure 2B). Also, a high number of tumors (23 cases, 53%)
were positive for HER2 FISH, of which 21 cases (48%) were
represented by high polysomy and only 2 cases (5%) by gene
amplification (illustrated in Figure 2C). EGFR and HER2
patterns were significantly associated (p  0.015): 19 cases
(43%) of tumors were positive and 11cases (25%) were
negative for both genes, while 14 cases (32%) had discordant
patterns; EGFR FISH positives were more likely to be HER2
FISH positives (19/29  66%) than EGFR FISH negatives
(4/15  27%).
Overall, the specimens with amplification of the EGFR
or HER2 genes exhibited clusters of loosely associated sig-
nals (Figures 2B, C) indicating that the amplification occurred
as homogenously staining regions. However, one specimen
displayed EGFR gene amplification as numerous, diffuse
signals mimicking the extrachromosomal double minutes
(Figure 2D). Heterogeneity for both EGFR and HER FISH
TABLE 1. Population Characteristics
Variable Categories Statistics
Age (years) Median 60.9  10.3
Range 38–79
Gender Male 23 (52.3%)
Female 21 (47.7%)
Smoking Never 23 (52.3%)
Ever 21 (47.7%)
Histology Adenocarcinoma 38 (86.4%)
Nonadenocarcinoma
(SqC, LC)a
6 (13.6%)
Differentiation Poor 10 (26.3%)
Moderate 22 (57.9%)
Well 6 (15.8%)
Not determined 6
Stage Early (I–II) 19 (43.2%)
Advanced (III–IV) 25 (56.8%)
Prior chemotherapy Yes 12 (27.3%)
No 32 (72.7%)
Survival after surgery (days) Median 2081
Range 250–2655
Tumor response (RECIST) Yes 17 (52%)
No 16 (48%)
Disease free interval (days) Median 375
Range 99–1818
Survival after gefitinib (days) Median 562
Range 69–724
Death Dead 15 (34.1%)
Alive 29 (65.9%)
a SqC, Squamous cell carcinoma; LC, Large cell carcinoma.
TABLE 2. EGFR FISH and Mutation Status According to Demographics
Variable Categories
EGFR FISH EGFR Mutation
Positive Negative p Positive Negative p
Age (years) Median 61.0 62.0 61.0 61.0
Gender Male 15 (65%) 8 p  0.9193 11 (48%) 12 p  0.0536
Female 14 (67%) 7 16 (76%) 5
Smoking Never 15 (67%) 8 p  0.9193 18 (78%) 5 p  0.016
Ever 14 (65%) 7 9 (43%) 12
Histology Adenocarcinoma 25 (66%) 13 p  0.9664 26 (68%) 12 p  0.0151
Nonadenocarcinoma
(SqC, LC)a
4 (67%) 2 1 (17%) 5
FISH, fluorescence in situ hybridization; EGFR, epidermal growth factor receptor.
a SqC, Squamous cell carcinoma; LC, Large cell carcinoma.
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patterns was common, with tumor foci showing nuclei with
high copy numbers (including gene amplification) in-
terspaced with nuclei with low copy numbers.
The association between FISH patterns and response to
the gefitinib treatment for 33 patients with measurable dis-
eases is shown in Table 3. Response to gefitinib was margin-
ally higher in EGFR FISH positive (65%) than negative
(29%) patients (p  0.0777). Patients with EGFR gene
amplification had a trend towards better benefit (response
in 4 of 4  100%) than patients with high polysomy
(response in 9 of 16  56%). HER2 FISH positive pattern
trended no impact, including 47% of responders (p 
0
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FIGURE 1. Frequencies of tumors
with distinct categories for the epi-
dermal growth factor receptor-flu-
orescence in situ hybridization
(EGFR-FISH) (A) and the HER2 FISH
(B) assays. Negative category in-
cludes disomy to low polysomy.
Positive category includes high
polysomy and gene amplification.
A
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C
D
FIGURE 2. Hybridization of the
non small-cell lung cancer (NSCLC)
sections with the epidermal growth
factor receptor EGFR/CEP7 (A, B,
D) and the PathVysion probe set
(C) showing EGFR high polysomy
(A), EGFR clustered gene amplifica-
tion (B), HER2 gene amplification
(C) and EGFR amplification as dou-
ble minutes (D).
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TABLE 3. Tumor Response in Relation to EGFR FISH, HER2 FISH, EGFR Mutation and KRAS
Mutation Status
Molecular marker Categories
Patients Tumor response
n % PR (%) SD PD p
EGFR Positive () 20 61 13 (65%) 1 6 p  0.0777
Negative () 13 39 4 (29%) 0 9
HER2 Positive () 17 52 8 (47%) 0 9 p  0.4426
Negative () 16 48 9 (56%) 1 6
EGFR and HER2 / 13 39 8 (62%) 0 5 p  0.2451
/ 7 21 5 (71%) 1 1
/ 4 12 0 (0%) 0 4 pa
/ 9 27 4 (44%) 0 5
EGFR mutation Positive () 20 61 17 (85%) 1 2 p  0.0001
Negative () 13 39 0 (0%) 0 13
EGFR FISH and EGFR
mutation
/ 16 48 13 (81%) 1 2 p  0.0029
/ 4 12 0 (0%) 0 4
/ 4 12 4 (100%) 0 0 pa
/ 9 27 0 (0%) 0 9
KRAS mutation Positive () 4 13 0 (0%) 0 4 p  0.0995
Negative () 26 87 14 (54%) 1 11
EGFR FISH and KRAS
mutation
/ 0 0 0 (0%) 0 0 pa
/ 17 57 10 (59%) 1 6
/ 4 13 0 (0%) 0 4 pa
/ 9 30 4 (44%) 0 5
FISH, fluorescence in situ hybridization; EGFR, epidermal growth factor receptor; PR, partial response; PD, progressive disease.
a p value could not be calculated because of blank cells.
TABLE 4. Time to Treatment Failure According to EGFRFISH, HER2 FISH, EGFR Mutation and KRAS
Mutation Status
Molecular marker Categories
Patients TTF after
Gefitinib (Days)
Median pn %
EGFR Positive () 29 66 169 0.722
Negative () 15 34 97
HER2 Positive () 23 53 121 0.1815
Negative () 21 47 144
EGFR and HER2 / 19 43 169 0.0179
/ 10 23 118
/ 4 9 56
/ 11 25 144
EGFR mutation Positive () 27 61 311 0.0001
Negative () 17 39 83
EGFR FISH and EGFR
mutation
/ 22 50 182 0.0001
/ 7 16 67
/ 5 11 916
/ 10 23 83
KRAS mutation Positive () 5 12 87 0.0248
Negative () 36 88 146
EGFR FISH and KRAS
mutation
/ 1 2 113 0.0767
/ 25 61 169
/ 4 10 57
/ 11 25 144
FISH, fluorescence in situ hybridization; EGFR, epidermal growth factor receptor; TTF, time to treatment failure.
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0.4426). Response rate was 62% of patients with EGFR
and HER2 FISH positive tumors, in 45% of patients with
EGFR or HER2 FISH positive tumors, and in 44% of
patients EGFR and HER2 FISH negative tumors. Time to
treatment failure (TTF) was not significantly associated
with EGFR or HER2 FISH positivity (Table 4). Overall
survival was not associated with patterns of EGFR FISH
(p  0.93) or HER2 FISH (p  0.69), as shown in Figure
3A, B. EGFR FISH patients with high polysomy (score
5) and true gene amplification (score 6) did not differ
regarding survival (p  0.6607; Figure 3C).
Among these 44 NSCLC patients, 27 (61%) had acti-
vating mutations in the tyrosine kinase domain of the EGFR
gene and, among 41 who were tested for KRAS mutations, 5
(12%) had point mutations in codons 12 or 13. Table 3 also
shows tumor response according to presence or absence of
EGFR and KRAS mutations, both individually and in com-
bination with EGFR FISH. EGFR mutation was significantly
associated with tumor response (p  0.0001) and prolonged
TTF (p 0.0001) or survival (p 0.02; Figure 4A and Table
4). EGFR FISH positivity was significantly associated with
presence of EGFR mutation (p  0.0060). Patients with
EGFR mutation were more likely to be EGFR FISH positive
(22/27  81%) than patients with wild type EGFR (7/17 
41%). EGFR mutations were present in all 6 tumors with
EGFR gene amplification and in 16 out of 23 tumors with
EGFR high polysomy (70%). Response rate was 81% of 16
cases positive for both EGFR FISH and mutation and all 4
EGFR FISH negative/EGFR mutation positive cases re-
sponded to gefitinib (Table 3).
Conversely, none of the 4 patients with KRAS mutation
(none of whom were EGFR FISH positive) or of the 13
patients with EGFR wild type (4 of whom were EGFR FISH
positive) benefited from gefitinib treatment. Presence of
KRAS mutation was significantly associated with TTF (p 
0.0248) but not with lack of response (p  0.0995) or overall
survival (p  0.4156, Figure 4B).
DISCUSSION
The EGFR FISH positive status had a borderline asso-
ciation to response of gefitinib treatment, but no impact on
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FIGURE 4. Effect on survival from the day of initiating ge-
fitinib treatment in recurrent non small-cell lung cancer
(NSCLC) after surgery by epidermal growth factor receptor
(EGFR) activating mutation (A) and KRAS mutation (B) status.-
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FIGURE 3. Effect on survival from the day of initiating ge-
fitinib treatment in recurrent non small-cell lung cancer
(NSCLC) after surgery by epidermal growth factor receptor
fluorescence in situ hybridization (EGFR FISH) status (A),
HER2 FISH status (B), and EGFR high polysomy and gene
amplification (C).
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survival in this cohort of Japanese NSCLC patients. These
results do not support a predictive role of the established
EGFR FISH assay to gefitinib sensitivity in Japanese NSCLC
patients. This observation contrasts with previous findings in
Caucasian NSCLC populations obtained by our group12,20,21 and
others,14 that had identified EGFR genomic gain by FISH as a
significant predictor of outcome to EGFR-TKIs. In the current
study, EGFR mutation was highly predictive of both response
and survival to gefitinib. Lack of predictive value of EGFR
FISH or EGFR gene copy numbers as assessed by quantitative
polymerase chain reaction have also been reported by Korean17
and Japanese26 groups. Therefore, there seems to be ethnic
differences as to whether EGFR genomic gain is predictive for
response or survival after geftinib treatment.
The clinical and demographical characteristics of this
Japanese cohort were distinctive, including high proportion
of female, never smokers, early stage disease, no prior che-
motherapy, and adenocarcinomas. Unselected cohorts of
Asian origin usually have higher frequency of females
(40%27) and never smokers (40%27) than Caucasians (34%
for females, 9% for never smokers according to Kobrinsky
et al.28). In addition, this cohort had one of the highest
reported frequencies of EGFR FISH tumors (68%) and
EGFR mutations (61%). Taken only studies that evaluated
gene copy numbers by FISH with identical or similar scoring
criteria, the frequency of EGFR FISH tumors ranged from
44 to 48% in Asian patients17,26,29 and from 32 to 45% in
Caucasian NSCLCs.14,21 EGFR activating mutations are well
known to be more prevalent in Asian (40–50% of adenocar-
cinomas27,30) than Caucasian NSCLCs (10% of adenocarci-
nomas25). Altogether, these findings substantiate the interest-
ing hypothesis that there are ethnicity-associated molecular
peculiarities in NSCLC.
The two EGFR gene markers, activating mutation and
genomic gain, were significantly correlated in this cohort.
Association between EGFR gene amplification and activating
mutations has been reported in NSCLC cell lines31 and
clinical specimens of Caucasian12 and Asian origins.17,32
Furthermore, the selective amplification of the mutant allele
was verified in the cell lines H3255, H827, PC-9, KT-2, KT-4
and Ma-1,31 as well as in Asian patients.32 These findings
support the hypothesis that there is a selection of cells
carrying the amplification of the mutant allele in lung tumor-
igenesis. Interestingly, high EGFR copy numbers due to
chromosomal aneusomy or structural rearrangements (high
polysomy) were also associated with mutations in this cohort
and in Caucasian NSCLC.33
Status of the HER2 gene in NSCLC has been poorly
explored and discrepant results have been reported in asso-
ciation with outcome to EGFR-TKIs.34 In this cohort, HER2
genomic gain showed up as a negative impact factor for
survival after gefinitib treatment, in contrast to our previous
results in an Italian cohort.34 Conversely, none of the five
KRAS mutant tumors showed treatment efficacy in this
study, in agreement with previously findings that KRAS
mutations are primary resistance factors to EGFR-TKIs.18,35
In summary, the study showed that the EGFR FISH
scoring criteria proposed for stratification of NSCLC for
therapy with EGFR-TKIs was not effective in Japanese pa-
tients as in Caucasian patients. Confirmation of these
results in larger cohorts is warranted and investigation of
factors that may underlie distinct molecular mechanisms of
activation of the EGFR pathway in these populations
should be investigated.
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